Jove
Visualize
Contact Us

Related Experiment Videos

Gene therapy for immunodeficiency diseases.

Alain Fischer1, Salima Hacein-Bey-Abina, Marina Cavazzana-Calvo

  • 1INSERM U 429, Hôpital Necker-Enfants Malades, Paris, France. alain.fischer@nck.ap-hop-paris.fr

Seminars in Hematology
|October 28, 2004
PubMed
Summary

Hematopoietic stem cell gene therapy shows promise for primary immunodeficiency diseases. Advances in gene transfer technology are making this a safer and more effective treatment for immunodeficiencies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paediatric-onset autoimmune cytopenia: How can we reduce the long-term mortality?

British journal of haematology·2026
Same author

Ribosomal RNA processing impairments in a B cell immunodeficient patient with WDR75 variants.

Journal of human immunity·2026
Same author

Pharmacological stabilization of hypoxia-inducible factor 1-α dampens the interferon response and promotes glycolysis in Aicardi-Goutières syndrome.

Nature communications·2026
Same author

Author Correction: Inactivation of cytidine triphosphate synthase 1 prevents fatal auto-immunity in mice.

Nature communications·2025
Same author

Inborn errors of immunity: Manifestation, treatment, and outcome-an ESID registry 1994-2024 report on 30,628 patients.

Journal of human immunity·2025
Same author

Lymphedema in patients with X-linked severe combined immunodeficiency.

The journal of allergy and clinical immunology. Global·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Immunology
  • Genetics
  • Biotechnology

Background:

  • Primary immunodeficiency diseases are suitable candidates for gene therapy targeting hematopoietic stem cells.
  • Severe combined immunodeficiencies (SCID) were the first conditions treated successfully with ex vivo gene therapy using retroviral vectors.

Purpose of the Study:

  • To highlight the potential of gene therapy for immunodeficiency diseases.
  • To discuss the role of advances in gene transfer technology.

Main Methods:

  • Review of existing gene therapy approaches for immunodeficiency.
  • Discussion of retroviral vector applications in ex vivo gene therapy.

Main Results:

  • Successful application of gene therapy in Severe Combined Immunodeficiencies (SCID).

Related Experiment Videos

  • Demonstration of hematopoietic stem cell-targeted gene therapy as a viable strategy.

    • Conclusions:

    • Gene therapy is a promising therapeutic strategy for primary immunodeficiency diseases.
    • Advancements in gene transfer technology enhance the safety and efficacy of gene therapy for these conditions.